Pediatric Solid Tumors, Pediatric Central Nervous System (CNS) Cancer
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Your participation could last up to 12 months depending on how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-For Part A of the trial, participant must have recurrent or refractory non-central nervous system (CNS) solid tumors
-For Part B of the trial, participant must have recurrent or refractory central nervous system (CNS) tumors
-Participant must not have other treatment options
-Participant must not have active or recent history of serious bleeding events
-Participant must not have active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses
-Participant must not have active or recent history of dangerously high blood pressure or headache, convulsions or coma related to high blood pressure
-Participant must not have an active, non-healing wound or bone fracture
-Participant must not have a history of organ transplant